Probiotics: From clinical trial to health claims success

02-Dec-2009 - Last updated on 28-Sep-2021 at 09:09 GMT

As a raft of non-positive opinions on probiotics floats down the health claims river, questions have been asked of the efficacy of the beneficial bacteria. Two experts discuss where we stand and how to get the good ship Probiotic back on course.

Chr Hansen's Svend Laulund and Joerg Gruenwald, president of CRO, Analyze & Realize talk to Stephen Daniells about what the recent EFSA rejections really mean for probiotics.

Laulund and Gruenwald also discuss how to fulfill EFSA's criteria and achieve a positive health claim. A good place to start would be correct characterisation of the strains, quickly followed by conducting studies in healthy populations.

These issues and more will be discussed at the upcoming NutraIngredients Health Claims 2010 conference in Brussels. Danone will discuss its response to the health claims process along with Provexis and others on Thursday, 10th December. Others include Unilever, analyze&realize, Cantox, academics, industry groups, lawyers and market experts. For more information and to register, please click here.